Agennix AG Raises € 9.8 Million (~$13 Million) in Private Placement with Existing Shareholders
Martinsried/Munich (Germany), Princeton, NJ and Houston, TX, March 21, 2010 - Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the Company has raised approximately € 9.8 million (approximately $13 million) in a private placement with existing shareholders. Agennix sold 1,870,523 shares at a price of € 5.22 per share. The newly issued shares, which were issued from authorized capital, represent 9.1% of Agennix's total shares outstanding after the transaction.
The Management Board and Supervisory Board of Agennix approved the capital increase at their meetings on March 21, 2010. The Company has resolved to increase its total share capital from € 18,707,432 by an amount of € 1,870,523 to a total share capital of € 20,577,955 by issuing 1,870,523 new ordinary bearer shares. The pre-emptive rights of the existing shareholders have been excluded.
"This private placement is the first part of our plan to re-finance the Company this year. We are pleased with the enthusiasm expressed by current shareholders for our talactoferrin development program," said Torsten Hombeck, Ph.D., Chief Financial Officer. "The funds we have raised will enable us to continue full-scale enrollment in the Phase 3 FORTIS-M trial in non-small cell lung cancer and to prepare for meetings with regulatory authorities to discuss the next steps following the positive Phase 2 trial of talactoferrin in severe sepsis."
Agennix intends to use the proceeds of this private placement to continue the development of talactoferrin and to fund ongoing operations.
Agennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients. The Company's most advanced program is talactoferrin, an oral targeted therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase 2 studies in non-small cell lung cancer as well as in severe sepsis. Talactoferrin is currently in Phase 3 clinical trials in non-small cell lung cancer. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has three sites of operation: Martinsried/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.
The shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended, or any state securities laws in the U.S., and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This announcement does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of shares in any state in the U.S. in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. There can be no guarantee that the Company will procure additional funding that is sufficient to continue its operations. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.